Site Logo
AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program
2020-01-15 08:01:33

AVROBIO has announced that it has received notice of clearance from the FDA regarding an Investigational New Drug (IND) application for AVR-RD-02, its investigational gene therapy for the treatment of Gaucher disease and has received consent from the first patient to enroll in its global Phase 1/2 trial.

The GAU-201 trial is actively recruiting in Australia and Canada, with additional sites planned in the United States.


Full press release can be found here